Introduction
Chemical penetration enhancers for topical and transdermal drug delivery have been studied extensively in the past several decades. 1, 2, 3 Typical enhancer studies, particularly in the pharmaceutical industry, have been skin permeation screening to match potential enhancers with drug candidates in transdermal or dermatological formulations. In these studies, the enhancers were evaluated when the test enhancer solutions with the drug were applied on the stratum corneum (SC) whereas the dermis side was in contact with the receiver solution that was usually buffered saline. Although this experimental approach is adequate in assessing the effects of skin penetration enhancers on the delivery of a particular drug and mimics the practical situation of skin delivery in practice, some aspects of enhancer mechanisms could not be systematically evaluated. Previous studies on the quantitative structure-enhancement relationship (QSER) of chemical enhancers have improved our knowledge in the field of skin penetration enhancers, 3, 4, 5 but the effects of these chemicals are still not easy to predict. Among these studies, a systematic approach was to investigate the mechanisms of action of skin penetration enhancers (a) under symmetric and equilibrium conditions (i.e., same enhancer conditions in the donor and receiver chambers in equilibrium with the SC), (b) with corrections for the changes in the chemical potential (activity) of the permeant in the enhancer solution with respect to that in the buffer solution (the control) to assess the effects of permeant activity alteration upon skin permeation in the presence of the enhancers, and (c) with model analyses to delineate the effects of permeation enhancement on transport across the lipoidal and pore transport pathways and only the lipoidal pathway was assessed. 6, 7 In this systematic and mechanistic approach, 6, 7 different from the asymmetric enhancer configuration (the test enhancer solution on the SC side and buffered saline on the dermis side), the symmetric and equilibrium conditions avoid the complex situation of an enhancer concentration gradient across the skin, in which the local permeation enhancement varies with the position within the membrane that makes mechanistic analyses of the data difficult. The correction of the changes in thermodynamic activities of the permeant in the enhancer solution with respect to that in the buffer solution (the control) when the thermodynamic activity of the permeant is altered in the presence of the enhancers allows direct comparison of flux enhancement at the same permeant thermodynamic activity. The parallel pathway model of lipoidal and pore transport pathways provides the framework to delineate the effects of the chemical enhancers on these 2 distinct pathways for understanding the mechanisms of the enhancers, particularly, the mechanism of action of chemical enhancers on the lipoidal pathway of the SC in skin permeation. With these strategies, the permeability enhancement factor, the ratio of the permeant flux with the enhancer solution to that of the control (without the enhancer), was calculated, and the enhancer concentrations to induce 10× flux enhancement at the same permeant thermodynamic activity (E = 10 concentrations) were determined. These enhancer concentrations were then compared to establish QSER of the chemical penetration enhancers. The results in these previous studies showed that the concentrations of the enhancers to induce 10× enhancement were related to the lipophilicities of the enhancers and the intrinsic potencies of these enhancers were relatively similar. However, enhancer concentrations other than E = 10 (and E = 4 in some cases) have not been analyzed.
Another method to evaluate skin penetration enhancers under the skin-enhancer equilibrium condition, particularly for highly lipophilic enhancers, was the direct equilibration of the skin with the liquid enhancers (or enhancers dissolved in an organic solvent) and subsequent skin transport experiments with buffered saline as donor and receiver solutions in the diffusion cells. 8, 9 This approach was based on the assumption that the depletion of the enhancers from the skin to the aqueous solution in the diffusion cell chambers was minimal, and essentially constant enhancer concentration could be maintained in the SC due to the high lipophilicity of the enhancers. The direct equilibration approach provided the condition that the enhancers in the SC were always at saturation with the solution in the diffusion cell chamber.
Otherwise, due to the low aqueous solubilities and extensive depletion of highly lipophilic enhancers in the aqueous phase in the diffusion chamber, the equilibrium condition would be difficult to achieve. Or, an aqueous reservoir system (e.g., micelles or cyclodextrins) for the enhancers in the diffusion cell would be required, and the assessment of the interactions between the reservoir system and skin would be needed. 10, 11 Employing the direct equilibration enhancer approach, a series of studies were completed to investigate QSER of highly lipophilic chemical enhancers and determine the maximum enhancement effects of the enhancers when the SC was saturated with the enhancers (i.e., at enhancer solubility in the SC lipids and the thermodynamic activity equivalent to the enhancer pure state). 8, 9 The present study collected data from the previous skin permeation studies of penetration enhancers that used the symmetric/equilibrium configuration and skin parallel pathway model and then analyzed the data to derive a relationship between skin permeation enhancement factor and enhancer concentration. The objectives were to (a) investigate the relationship between skin permeation enhancement and chemical enhancer concentration for QSER and (b) examine a QSER of enhancer concentration and octanol/water partition coefficient to predict skin permeation enhancement. An important goal was to provide guidance to semiquantitatively predict permeation enhancement of the SC lipoidal pathway under the influence of the chemical enhancers using enhancer concentrations and the general physiochemical properties of the enhancers such as Koct. The "threshold" enhancer concentration required to induce permeation enhancement was also investigated.
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Model and Equation
According to previous studies, 12, 13, 14 skin permeation enhancement is related to enhancer concentration and the relationship can be expressed as: (1) where E is the enhancement factor of the lipoidal pathway in the SC under the influence of the chemical enhancer, C is the concentration of the enhancer in the aqueous medium in equilibrium with the skin, and α is the enhancer potency parameter. A higher α value indicates a lower enhancer concentration is required to induce the same permeation enhancement effect for the chemical enhancer, and hence, higher effectiveness of the enhancer. In the absence of the enhancer, when C = 0, enhancement factor = 1. The enhancer potency parameter α can be further expressed as the intrinsic potency of the enhancer (α') and enhancer octanol/water partition coefficient (the intrinsic potency was later found to be a relatively constant value for the studied enhancers, see Results and Discussion section):
(2)
where Koct is the octanol/water partition coefficient of the enhancer and n is the coefficient of the linear free energy relationship between the SC lipid microenvironment and octanol, similar to the relationships commonly used for isotropic solvents. 15 The coefficient accounts for the difference between the polarities of the environment in octanol and SC lipid microenvironment for the partitioning of the enhancer. To assess the effect of enhancer lipophilicity on its potency, parameters n and α' were obtained using:
(3)
As solute partitioning into lipid bilayer is also related to bilayer free volume and solute molecular size, 16 enhancer molecular weight (MW) can affect its partitioning into SC lipid lamella. Including the effect of MW on enhancer partitioning into SC lipid microenvironment, the effect of MW can be described as follows:
where β is the coefficient for MW and γ is constant.
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Data Collection and Analysis
Enhancement factor data were collected from previous studies of chemical penetration enhancers that used the symmetric/equilibrium configuration and skin parallel pathway model. Only data meeting these experimental criteria were used. These penetration enhancers have logarithm of octanol/water partition coefficient (Log Koct) ranging from −1 to 5 and MW from 46 to 320 Da. Data of short-chain alkanols were obtained from skin permeation studies of hydrocortisone, β-estradiol, and estrone across hairless mouse The data were analyzed for the relationship between enhancement factor and enhancer concentration.
For each enhancer, the logarithms of the enhancement factors (for the lipoidal transport pathway after corrections for the activity coefficients) were plotted against the aqueous enhancer concentrations. Linear regression analyses and statistics were performed using Microsoft Excel (Redmond, WA) on the enhancement factor versus concentration relationships (Eq. 1) by setting y-intercept = 0. The linear least squares slopes (the enhancer potency parameter α) and R 2 of the regression analyses are presented. All α values were used in the analyses of the present study regardless of the R 2 values. To compare the data, plots of the logarithms of the enhancement factors versus concentrations of the enhancers with and without adjustment using Koct are presented. Table 1 , Table 2 summarize the results of the linear least squares regression analyses of Log E versus concentration of the enhancers (Eq. 1). The regression analysis of each enhancer shows good correlation between Log E and enhancer concentration with R 2 > 0.85 for most enhancers. The slopes α of log E versus concentration for the enhancers ranged from 10 −1 to 10 4 , up to 5 orders of magnitude differences in the effectiveness of the chemicals as skin penetration enhancers. The ability of a penetration enhancer partitioning and diffusing into the SC could affect the effectiveness of the enhancer. In addition to enhancer lipophilicity, molecular charge and MW, which govern enhancer partition and diffusion behaviors in lipids, could affect enhancer potency. The molecular shape and size of an enhancer also affect its intercalation in the SC intercellular lipids and enhancer-induced lipid fluidization. The majority of the penetration enhancers in Table 1 , Table 2 are uncharged, so possible effects of molecular charges on enhancer potency could not be systematically investigated in the present study. For enhancer molecular size, the influence of MW on enhancer potency was examined using regression analyses of Equation 4. No significant effect of MW on enhancer potency in addition to that of Log Koct was found: n and R 2 obtained using Equation 4 (n = 0.91, R 2 = 0.970) are essentially the same as those of Equation 3 (Fig. 1 ).
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Correlations Between Enhancement Factor and Enhancer Concentration
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Correlations Between Enhancement Factor and Enhancer Concentration With Koct
With the correlation between α and Log Koct for the enhancers in Figure 1 
Enhancement Factor, Enhancer Concentration, and Koct for Each Enhancer Class
The "Log E versus C • Koct" relationships were further examined based on their chemical classes and structures. Figure 3 
Figure 4
Relationships between enhancement factor and C • Koct for the studied penetration enhancers compared with alkanol data. Each data point represents a "C • Koct" condition of an enhancer.
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Comparison Between HMS and HEM Enhancement Factors and Data Regression Analyses
Figure 5
Relationships between enhancement factors and concentration (C • Koct) of all studied enhancers including data of lipophilic enhancers when they were saturated in HEM. Each data point represents a "C • Koct" condition of an enhancer. The dotted lines bracket the data.
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In the regression analysis using Equation 2 and all the enhancers (including the data from enhancers saturated in HEM), n = 0.94 was determined. This value is larger than the coefficient of 0.7-0.86 for Log Koct to account for the difference between the polarities of octanol and the SC lipid-partitioning domain for skin permeation. 25, 26, 27 Different from skin permeation in which octanol is more lipophilic than the SC partitioning domain, the n = 0.94 value in the present study suggests that the SC microenvironment for the enhancer action to induce permeation enhancement is similar to octanol. 6, 20 Assuming that the skin lipid domain can be described by octanol (n = 1.0 in Eq. 2), linear least squares regression analyses were performed using the data in Figure 5 . Table 3 presents the results of the regression analyses.
Table 3Linear
Least Squares Regression Analyses of "Log E versus C • Koct" for the Enhancers Studied in Figure View Table in HTML aNot applicable, linear regression forcing y-intercept = 0.
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Enhancer Concentration and Koct to Predict Skin Permeation Enhancement
A main finding in the present study is the importance of Koct as a parameter to predict the effects of penetration enhancers. Enhancer Koct (i.e., lipophilicity) can be used to assess enhancer potency. This is consistent with the finding that enhancer effects are related to enhancer concentration in the SC barrier, 28 and hence enhancer partitioning into the SC lipids and enhancer lipophilicities. Particularly, a correlation was found between the enhancer potency parameter α and enhancer Koct (Fig. 1 ). Using this correlation, the potency of an enhancer for skin permeation enhancement under the conditions studied can be predicted. The R 2 value of the regression analysis in Figure 1 suggests satisfactory predictivity.
Under the conditions in the present study, skin permeation enhancement can also be predicted by the thermodynamic activity of the enhancer in the formulation and its equilibrium activity in octanol (i.e., C • Koct). The values of C • Koct were shown to correlate with skin permeation enhancement. The higher the aqueous enhancer concentration in the chamber (or formulation) and the higher its lipophilicity, the higher is the skin permeation enhancement. This correlation suggests that C • Koct can be a predictor of skin permeation enhancement. The significance of Koct suggests that octanol could mimic the microenvironment for the enhancer action in the SC. According to Table 3, under the conditions studied. This value is not highly dependent on the chemical structures among the enhancers examined in the present study (Fig. 5) as the data scatter of this "threshold" value (e.g., ∼0.5-3
M for E = 2) is within an order of magnitude from each other. This suggests that the differences in the intrinsic potencies of the enhancers are generally small. There is also a general trend that the n-alkyl chain enhancers are more effective than branched alkyl chain enhancers and some carbon ring-structure enhancers (e.g., menthol and cineole). The disruption of SC lipid lamellar packing is a major mechanism of skin penetration enhancers. 28, 29, 30, 31 The enhancement effect is therefore related to the intercalation of the enhancers in the SC lipid structure and the amounts of the enhancers embedded in the lipids. 28 The nalkyl chain enhancers could be more disruptive to the structural order of the SC intercellular lipid lamella compared to the branched alkyl and ring-structure enhancers when the enhancers partition and intercalate in the lipids. It is also possible that the branched alkyl and ring-structure enhancers do not partition into lipid lamella as well as the n-alkyl chain enhancers do.
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Considerations for Using Enhancer Concentration and Koct as Predictors of Skin Permeation Enhancement
Considerations should be given to the limitations of predicting permeation enhancement using the "Log E versus C • Koct" relationship. First, symmetric and equilibrium conditions were used in the skin permeation experiments to determine the enhancement factors analyzed in the present study. In transdermal delivery in practice, an asymmetric condition is normally encountered, in which the enhancers are only applied to the skin in the donor chamber. The asymmetric condition would likely result in a lower enhancement factor compared to that under the symmetric condition. The difference between enhancer-induced skin permeation effects under the asymmetric and symmetric conditions was examined previously. 32 In this previous study, a correlation between the enhancement factors under the asymmetric and symmetric conditions was observed, with ∼2-3× lower flux enhancement under the asymmetric condition. The enhancement factor estimated using the "Log E versus C • Koct" relationship in the present study therefore could overestimate the permeation enhancement effect under the asymmetric enhancer condition in practice.
Skin permeation after formulation application in practice is in transient state. Steady-state permeation normally cannot be achieved due to the transport lag time, drug and enhancer depletion, and other changing conditions in the topical and transdermal formulations. The present analysis used steady-state permeation data. As skin permeation enhancement is related to the concentration of the enhancer in the SC, drug permeation is affected by enhancer permeation kinetics (e.g., from the formulation to its site of action in SC). The analysis did not take into account the diffusion of enhancers in the SC. The analysis also did not consider the changes in enhancer concentration in the formulation due to possible enhancer depletion when a finite dose of an enhancer is used. Enhancer depletion could be important for lipophilic enhancers due to their high skin uptake.
The permeation enhancement factors predicted from the correlation in the present study could be limited to permeants of certain physicochemical properties. The model permeants in the enhancer analysis were moderately lipophilic with MW in the ∼270-360 Da range. Permeant molecular size (or MW) could affect enhancer-induced permeation enhancement. 33 For example, skin permeation enhancement was found to be a function of permeant MW (see Supplementary Material) . 7 The same trend was observed in skin permeability enhancement results from molecular dynamics simulations. 28 Therefore, permeants of MW different from the ∼270-360 Da range would likely deviate from the "Log E versus C • Koct" relationship in the present study. In addition to MW, permeant lipophilicity dictates the pathway for its skin permeation.
The SC intercellular lipids are the predominant pathway for the permeation of lipophilic permeants whereas the pore pathway is the predominant permeation pathway for polar and ionic permeants. Skin permeation enhancement of the pore pathway was not determined in the present analysis, and therefore, the "Log E versus C • Koct" relationship should not be applied to polar and ionic permeants.
Aqueous media were the donor and receptor solutions in the skin permeation studies in the present analysis for the permeability-enhancing effects and baseline permeability values. The results are therefore only appropriate for drug delivery systems that provide skin occlusion when the skin is fully hydrated. In addition, the skin permeation studies did not include nonaqueous vehicles and cosolvents.
The "Log E versus C • Koct" relationship is therefore expected to be for aqueous formulations. For skin permeation of a nonaqueous formulation, the vehicle (or cosolvent) alters the thermodynamic activity of the enhancer and hence affects the partitioning tendency of the enhancer from the vehicle into the SC. In this case, the vehicle can result in lower concentration of the enhancer at its site of action in the SC.
The variability in the "Log E = 0.32 • C • Koct" relationship ( Fig. 5 and Table 3) 
